Skip to main content
SpringerLink
Log in

Jevtana: updates in Japan regarding febrile neutropenia

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. G-CSF is administered to prevent FN from the first cycle of cancer chemotherapy when the patient has no neutropenia or pyrexia.

Reference

  • Ministry of Health, Labour and Welfare & Pharmaceutical and Food Safety Bureau, Japan. Cabazitaxel Acetonate and Severe Febrile Neutropenia. Pharmaceuticals and Medical Devices Safety Information : 4-15, No. 320, Jan 2015. Available from: URL: http://www.pmda.go.jp/files/000203635.pdf

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jevtana: updates in Japan regarding febrile neutropenia. Reactions Weekly 1545, 4 (2015). https://doi.org/10.1007/s40278-015-9095-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-015-9095-1

Search

Navigation